Medical Information
In order to provide you with relevant and meaningful content we need to know more about you.
Please choose the category that best describes you.
This content is intended for U.S. Healthcare Professionals. Would you like to proceed?
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
LMD (dextran 40) is indicated for use in the adjunctive treatment of shock or impending shock due to hemorrhage, burns, surgery or other trauma. It is not indicated as a replacement for whole blood or...
LMD (dextran 40) is administered by I.V. infusion only.
Dextran 1 should be administered prior to administration of clinical dextran solutions.
LMD (dextran 40) is contraindicated in patients with known hypersensitivity to dextran, in those with marked hemostatic defects of all types (thrombocytopenia, hypofibrinogenemia, etc.) including those...
Although infrequent, severe and fatal anaphylactoid reactions consisting of marked hypotension or cardiac and respiratory arrest have been reported, most of these reactions have occurred in patients not previously...
Antigenicity of dextrans is directly related to their degree of branching. Since LMD (dextran 40) has a low degree of branching, it is relatively free of antigenic effect. However, a few individuals have...
LMD (dextran 40) is a sterile, nonpyrogenic preparation of low molecular weight dextran (average mol. wt. 40,000) in 5% Dextrose Injection or 0.9% Sodium Chloride Injection. It is administered by intravenous...
The fundamental action of LMD (dextran 40) is the enhancement of blood flow, particularly in the microcirculation. This enhancement is due to:
10% LMD in 5% Dextrose Injection (Dextran 40 in Dextrose Injection, USP) is supplied as follows:
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this product, click the link below to submit your information: Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer product, please call Pfizer Medical Information at (800) 438-1985.
